Making Cancer-Targeted Binding “Reversible”: XPO1 Inhibitor Extends Survival and Reduces Blood Cell Toxicity in Mice

Cancer-targeted drugs must not only hit tumors but also leave enough room for normal tissues. A preclinical study published in *Nature Communications* introduces FR-027, a reversible covalent XPO1 inhibitor. It delayed disease and extended survival in multiple mouse cancer models, without causing significant decreases in platelets, lymphocytes, or neutrophils during the study, presenting a safety profile distinct from that of existing comparator drugs.

XPO1, also known as CRM1, is an important gateway through which cells transport proteins and RNA from the nucleus to the cytoplasm. Many cancer cells use this pathway to remove tumor suppressor proteins, thereby sustaining growth; blocking XPO1 can retain these proteins in the nucleus and drive cancer cells toward apoptosis. This target has been clinically validated, but inhibiting XPO1 may also disrupt normal cells, making side effects such as reduced blood cell counts a limitation of treatment.

FR-027 likewise forms a covalent bond with the cysteine residue Cys528 in the nuclear export signal-binding groove of XPO1. The key difference is that this binding can be reversed. Structural analysis showed that the drug keeps the binding groove in a closed conformation but, unlike selinexor and eltanexor, which were used as comparators in the study, does not promote degradation of the XPO1 protein. In other words, it does not change the target; instead, it attempts to redraw the boundary between efficacy and toxicity through different binding chemistry and a different subsequent fate for the protein.

In cell experiments, FR-027 showed inhibitory potency comparable to that of selinexor and eltanexor across multiple tumor types. Animal studies included human tumor xenografts and syngeneic tumor models with intact immune systems; the results showed that FR-027 delayed disease progression and extended overall survival. Researchers also observed efficacy in intracranial tumor models, consistent with the oral bioavailability and ability to cross the blood–brain barrier described by a KU Leuven research program, thereby providing further rationale for research into brain tumors such as glioblastoma.

The safety signal was the most notable aspect of the study. After intensive, repeated dosing, the mice did not develop significant thrombocytopenia, lymphopenia, or neutropenia. On this basis, the research team suggested that reversible binding without promoting XPO1 degradation may help reduce hematologic toxicity. However, this remains a mechanistic hypothesis supported by animal studies and cannot be used to directly infer that humans could tolerate higher doses or that the drug would have a better therapeutic window than existing treatments.

FR-027 remains at the preclinical stage. Differences in drug metabolism across species, the effects of long-term inhibition of nuclear export, and the tumor concentrations actually achievable in patients with brain tumors have yet to be addressed by human data. The paper also disclosed related patent applications and a licensing relationship between KU Leuven and an XPO1 drug developer. In addition to formal toxicology and dose studies, the next steps will require direct comparisons of efficacy, hematologic toxicity, and risks to other organs in clinical trials before it can be determined whether “reversibility” truly translates into a safety advantage that patients can experience.